Skip to main content
Journal of Enzyme Inhibition and Medicinal Chemistry logoLink to Journal of Enzyme Inhibition and Medicinal Chemistry
. 2020 Jul 1;35(1):1433–1441. doi: 10.1080/14756366.2020.1786819

LC-QTOF-MS analysis of xanthone content in different parts of Garcinia mangostana and its influence on cholinesterase inhibition

Kooi Yeong Khaw a, Chun Wie Chong a, Vikneswaran Murugaiyah b,
PMCID: PMC7717613  PMID: 32608273

Abstract

Mangosteen is one of the best tasting tropical fruit widely cultivated in Southeast Asia. This study aimed to quantify xanthone content in different parts of Garcinia mangostana by LC-QTOF-MS and determine its influence on their cholinesterase inhibitory activities. The total xanthone content in G. mangostana was in the following order: pericarp > calyx > bark > stalk > stem > leaves > aril. The total xanthone content of pericarp was 100 times higher than the aril. Methanol extracts of the pericarp and calyx demonstrated the most potent inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.90 and 0.37 µg/mL, respectively. Statistical analysis showed a strong correlation between xanthone content and cholinesterase inhibition. Nonmetric multidimensional scaling analysis revealed α-mangostin and γ-mangostin of pericarp as the key metabolites contributing to cholinesterase inhibition. Due to the increasing demand of mangosteen products, repurposing of fruit waste (pericarp) has great potential for enhancement of the cognitive health of human beings.

Keywords: α-Mangostin, γ-mangostin, Garcinia mangostana, LC-QTOF-MS, xanthone, cholinesterase inhibition

Introduction

Garcinia mangostana (mangosteen) is well known as ‘the queen of fruits’ and is one of the best tasting tropical fruits. The mangosteen fruit has dark purple or reddish pericarp, with white, soft and juicy edible aril that has slightly acidic and sweet flavour. Garcinia mangostana is recognised as one of the novel food in Asia, European Union, and the US due to its high antioxidant potential and traditional consumption in its countries of origin. In the US, mangosteen juice is the second best-selling herb and botanical with the total sales volume of USD 176 million and ranked 22nd for the best-selling supplement1.

Phytochemical analysis has been conducted to analyse chemical constituents of G. mangostana (mainly xanthones) using the conventional HPLC-UV2 and TLC3 methods. Although these methods have been routinely used for the analysis of xanthones, they are relatively insensitive. A HPLC-DAD-MS method has been developed to quantify seven xanthones in the pericarp, aril segments and the functional beverage4 and six xanthones have been identified and quantified by LC–ESI-MS5. However, there is little or no information about the content of xanthones such as α-mangostin in other parts of mangosteen tree. The variation in xanthone content in extracts prepared using different extraction solvents (organic or aqueous) also remained unknown. Therefore, developing more powerful analytical tools and methods for the simultaneous and systematic quantification of xanthones in different parts of G. mangostana is of great interest. Liquid chromatography-quadrupole of flight tandem mass spectrometric (LC-QTOF-MS) allows the generation of mass information with greater accuracy and precision and has been used to determine the molecular formula at low part per million concentrations.

Severe loss of cholinergic neurons in the nucleus basalis and associated areas that form the cholinergic forebrain area resulted in up to 90% reduction in the activities of the enzyme choline acetyltransferase, which is needed for the synthesis of the neurotransmitter acetylcholine6,7. It is evident that acetylcholine, a neurotransmitter essential for processing memory and learning, is decreased in both concentration and function in patients with Alzheimer’s disease as a result of reduction in its synthesis and rapid breakdown by cholinesterase enzymes8. Current available strategy for the treatment of Alzheimer's disease relies on blocking the breakdown of acetylcholine through cholinesterase inhibitors to improve brain functions, and possibly slow deteriorations of cognitive functions9. Excellent candidates from natural products are shown to improve cognitive function including Gingko biloba leaves extract, huperzine from Huperzia serrata, green tea, ginger and caffeine10–13, whereby some of them work by cholinesterase inhibition.

Our previous study showed that the methanol extract of G. mangostana pericarp and its six xanthones constituents possessed potent cholinesterase inhibitory activities with IC50 value in the range of 1.28–8.0 µg/mL, whereby garcinone C, γ-mangostin and α-mangostin were the most potent inhibitors among the tested xanthones14. Over the course of our continuing study to explore the potential cognitive enhancement properties of this plant, we aimed to compare the xanthone content in different parts of the plant and its correlation with their bioactivities. Herein, we report the analysis of six bioactive xanthones in aqueous and organic extracts of different parts of G. mangostana using LC-QTOF-MS and evaluate their cholinesterase inhibitory activities for the first time, and correlate the influence of xanthone content on cholinesterase inhibitory potential.

Materials and methods

Chemicals and reagents

Acetylthiocholine iodide (ATCl), acetylcholinesterase from Electrophorus electricus (electric eel) (AChE), bovine serum albumin (BSA), 5,5′-dithiobis [2-nitrobenzoic acid] (DTNB), butyrylcholinesterase from equine serum (BChE), S-butyrylthiocholine chloride and galantamine were purchased from Sigma Chemicals (St. Louis, MO, USA). HPLC grade methanol was purchased from Merck (Darmstadt, Germany). Formic acid was purchased from R & M Chemicals (United Kingdom). Marker compounds: 8-deoxygartanin (97.5% purity) was purchased from Chromadex (Irvine, CA, USA) while γ-mangostin (98.37% purity) and garcinone C (>98% purity) were obtained from Chengdu Biopurify (Chengdu, China). Mangostanol (>95% purity), 3-isomangostin (>90% purity) and α-mangostin (>95% purity) were isolated in-house following procedures described previously14.

Plant materials

The raw materials of G. mangostana were obtained from Penang, Malaysia. The plant materials were obtained from a single tree of about 5 years old and 3m height. The green mature leaves, bark, stem and whole ripe purplish fruit were collected for this study. A voucher specimen (No. 11247) has been deposited at the herbarium, School of Biological Sciences, Universiti Sains Malaysia, Malaysia. The plant materials were separated into the following parts: leaves, bark, stem and whole fruit (the whole fruit was further separated into pericarp, aril, calyx, and stalk).

Preparation of organic and aqueous extracts of different parts of G. mangostana

The different parts of G. mangostana were extracted with methanol or distilled water by using the maceration method. In brief, the powdered samples (20 g) were extracted with methanol or distilled water for 3 days at 60°C at raw material to solvent ratio of 1:10 (w/v). Fresh solvents were replenished every day and the resulting extracts were filtered through filter paper. The pooled extracts were evaporated under vacuum and lyophilised. The yields of the lyophilised extracts were between 0.8% and 38.2%.

LC-QTOF-MS analyses

Preparation of the marker compounds for optimisation of MS

For optimisation of MS conditions, stock solutions of the marker compounds at 1000 µg/mL were prepared by accurately weighing each marker compound, then dissolving them in HPLC grade methanol and storing at 4 °C prior to analysis. Working solutions were prepared by diluting an aliquot of the stock solution with methanol to the desired range of concentrations. All the diluted solutions were filtered through a 0.22 µm PTFE syringe filter (Whatman, UK) prior to injection into the LC system.

LC-QTOF-MS

The LC-QTOF-MS system consisted of Ultimate 3000 RSLC (Dionex; Sunnyvale, CA) coupled to micrOTOF-QII quadrupole time-of-flight mass spectrometer in positive electrospray mode (Bruker; Billerica, MA). A Zorbax SB-C18 (150 mm X 2.1 mm, 3.5 µm) column was used for the separation of compounds of interest. The column temperature was maintained at 25 °C. Mobile phase consisted of 0.1% formic acid in ultra-high quality water (A) and 0.1% formic acid in methanol (B) at a constant flow rate of 0.2 ml/min. Gradient programme was as follows: 0–6 min 40% A, 6–15 min 10% A, 15.1–18 min 0% A, 18.1–23 min 40% A. Optimised mass spectrometer conditions were: capillary voltage 4500 V; nebuliser pressure 5 bar; dry gas 6 L/min; gas temperature 300 °C; collision energy isomangostin and α-mangostin (15 V), garcinone C (30 V), crystal violet 372 (40 V), 8-deoxygartanin (11 V), γ-mangostin (12 V), mangostanol (20 V).

Calibration curves, linearity ranges, limits of detection (LODs) and limits of quantification (LOQs)

The linear dynamic ranges of the LC-QTOF-MS method for the determination of the six xanthones were evaluated from a set of five solutions, at concentrations ranging from 0.025 to 50 µg/mL (some of the xanthones had much lower linear range, refer to Table 1). Each individual marker compound at a fixed concentration was consecutively injected three times. The calibration curves were constructed by plotting peak height against the analyte concentrations and the linearity of six compounds were evaluated by linear regression analysis. The LODs of the xanthones were in the range of 5 to 500 ng/mL, while their LOQs were in the range of 25 to 5000 ng/mL.

Table 1.

Linearity, LOD and LOQ of the xanthones of Garcinia mangostana.

Compound Regression equation Linear range (ng/mL) R2 LOD (ng/mL) LOQ (ng/mL)
Mangostanol (1) y = 0.176164x ± 0.045660 1000–10000 0.9998 500 1000
3-Isomangostin (2) y = 1.000952x ± 0.002474 25–1000 0.9999 5 25
Garcinone C (3) y = 0.035076x ± 0.030565 5000–50000 0.9987 120 5000
γ-Mangostin (4) y = 0.389182x ± 0.000753 1000–5000 0.9910 90 1000
8-Deoxygartanin (5) y = 0.595092x ± 0.003890 25–500 0.9969 10 25
α-Mangostin (6) y = 0.480042x ± 0.151938 1000–10000 0.9992 50 1000

Quantification of xanthones by LC-QTOF-MS

Volumes of 5 µL of the extracts were injected into the system. The concentration and profile of xanthones in the extracts were determined using optimised LC-QTOF-MS parameters. Peak identifications were made by matching the retention times and the fragmentation pattern with those of the marker compounds and were quantified using the internal standard method.

Cholinesterase inhibition assay

Cholinesterase inhibitory potential of the extracts of different parts of G. mangostana were determined by the spectrophotometric method as described previously15. For both AChE and BChE inhibitory assay, 140 µL of 0.1 M sodium phosphate buffer (pH8) was added to a 96 wells microplate followed by 20 µL of test samples and 20 µL of 0.09 units/mL of AChE or BChE enzyme. Then, 10 µL of 10 mM 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB) was added into each well followed by 10 µL of 14 mM of acetylthiocholine iodide or S-butyrylthiocholine chloride. The enzymatic hydrolysis reaction as indicated by the absorbance was measured for 30 min using Tecan Infinite 200 Pro Microplate Spectrometer at 412 nm. Galantamine was used as a positive control for both assays. Absorbencies of the test samples were corrected by subtracting the absorbencies of their respective blank.

Percentage inhibition was calculated using the following formula:

Percentage inhibition=(Absorbance of controlAbsorbance of extract) × 100%Absorbance of control

Statistical analysis

Nonmetric multidimensional scaling (NMDS) was used to project the pairwise differences in the detected metabolites between samples. The method was selected over principle component analysis due to the presence of missing data (concentration below detection limits). A bubble plot was superimposed on the NMDS to illustrate the relative concentration of the metabolites across samples. NMDS and the corresponding bubble plots were constructed using the PRIMER7 programme package (PRIMER-E, UK). The differences in IC50 across plant part clusters were presented using the box plot. Significant differences between the mean values were inferred based on analysis of variance (ANOVA). Subsequent post-hoc analysis was conducted using Dunnett’s Test. Relationship between the xanthone content and IC50 of AChE and BChE was tested using Pearson’s correlation. The relationship was illustrated using a scatter plot. Both box plot and scatter plot were generated using ggplot2 package implemented under the R programme.

Results and discussion

Optimisation of chromatographic method

For the LC-QTOF-MS method optimisation, various chromatographic parameters including mobile phase compositions, analytical columns and elution programmes were systematically optimised to acquire a better peak resolution and capacity for identification and quantification of xanthones between their adjacent peaks in the chromatogram. A small amount of formic acid was introduced to increase the peak shape and as an ionic modifier to enhance the mass response of the marker compounds in the G. mangostana extracts. Different reverse phase (RP) columns were used for optimisation, and Zorbax SB-C18 column was chosen due to its superiorities at satisfactory separations for all investigated analytes, acceptable peak shape, and low system back-pressure. A gradient elution programme was optimised to obtain good baseline separation for all marker compounds. Representative total ion chromatograms for the methanol and aqueous extracts of different parts of G. mangostana are shown in Figure 1.

Figure 1.

Figure 1.

Representative total ion chromatogram of the methanol extracts (A) and aqueous extracts (B) of different parts of Garcinia mangostana. (1) Mangostanol ; (2) 3-Isomangostin ; (3) Garcinone C ; (4) γ-Mangostin ; (5) 8-Deoxygartanin ; (6) α-Mangostin.

Ionisation pattern of xanthones in ESI

Both positive and negative ionisation modes are acceptable for the analysis of xanthones. Several groups have reported the analyses of xanthones by LC-MS in positive ionisation mode. Li et al. has identified the bioactive prenylated xanthones that inhibited the growth of Ralstonia solanacaerum using LC-MS in positive mode16. Likewise, mangiferin, a xanthone derivative was analysed and quantified in Swertia chirayita methanolic extract using LC-ESI/MS in positive mode17. In contrast, there are a number of studies that analysed and quantified prenylated xanthones in G. mangostana in negative ionisation mode MS4,18. To obtain structural information, MS/MS studies of the molecular ion of each compound were performed. All the compounds were characterised by the interpretation of their exact molecular weight, molecular formula, and characteristic MS/MS fragment ions data acquired from the Q-TOF-MS (Figure 2). The diagnostic fragmentation patterns of different xanthones are tabulated on the basis of Q-TOF-MS data of components in G. mangostana and six authentic marker compounds. The fragmentation pathways of the xanthones derived from G. mangostana were previously discussed4.

Figure 2.

Figure 2.

Fragmentation patterns of the xanthones. (1) Mangostanol, (2) 3-Isomangostin, (3) Garcinone C, (4) γ-Mangostin, (5) 8-Deoxygartanin, (6) α-Mangostin.

Method validation and xanthones quantification

As shown in Table 1, all xanthones demonstrated good linearity (r2 > 0.99) over a range of concentrations used. The LODs and LOQs of xanthones were in the range of 5–500 ng/mL and 25–5000 ng/mL, respectively. The xanthone content in methanol and aqueous extracts of different parts of G. mangostana are summarised in Table 2. The highest total xanthone content was found in the methanol extract of pericarp (521.2 mg xanthones/g of extract or 185.5 mg of xanthones/g of dry powdered raw material). The total xanthone content in the methanol extracts of different parts of the plant were in the following descending order: pericarp > calyx > bark > stalk > stem > leaves > aril. Interestingly, the methanol extract of aril had 100 folds lower in total xanthone content compared to pericarp. A previous study quantified xanthones in the aril and pericarp of G. mangostana using HPLC-DAD-MS4. The authors reported 8.6 mg and 0.43 mg of γ-mangostin, 1.4 mg and 0.26 mg of 8-deoxygartanin and 33.2 mg and 2.13 mg of α-mangostin in each gram of pericarp and aril dried materials, respectively. The levels of the three xanthones in pericarp dry material were lower; however, their levels in aril were higher compared to our present study. The difference could be due to the difference in the ripening stages of the fruits and the extraction solvent used, which was methylene chloride. On the other hand, a more recent study on the xanthone analysis of six different maturity levels of mangosteen rind extract using LC-MS/MS analysis reported the γ-mangostin levels in the range of 0.94–66.13 mg per gram of extract, which were comparable with the present study (57.0 mg/g extract)19. In contrast to the methanol extracts, total xanthone content in the aqueous extracts are relatively much lower attributed to the relatively non-polar nature of the prenylated xanthones. The total xanthone content for aqueous extracts was in the range 2.9–7.3 mg/g of extract. Aqueous extract of bark had the highest total xanthone content followed by pericarp, stem and leaves. In addition, calyx, aril and stalk had almost similar total xanthone content.

Table 2.

Xanthone content in the methanol and aqueous extracts of different parts of Garcinia mangostana.

Sample     Content of bioactive xanthones (n = 3) (mg/g)
Relative distributionc
Yield (%) Mangostanol (1)
3-Isomangostin(2)
Garcinone C (3)
γ-Mangostin (4)
8-Deoxygartanin (5)
α -mangostin (6)
Total
1 2 3 4 5 6
Extracta RWb Extracta RWb Extracta RWb Extracta RWb Extracta RWb Extracta RWb Extracta RWb
Methanol extract
Pericarp 35.6 8.6 ± 0.4 3.1 10.4 ± 0.6 3.7 0.5 ± 0.1 0.2 57.0 ± 12.7 20.2 11.5 ± 0.6 4.1 403.9 ± 13.1 143.7 521.2 185.5 0.8 1 0.06 5.4 1.1 38.6
Calyx 38.2 35.3 ± 2.6 13.5 7.7 ± 0.3 2.9 0.6 ± 0.0 0.2 37.2 ± 1.9 14.2 13.2 ± 1.2 5.0 221.0 ± 11.2 84.0 311.5 118.9 4.5 1 0.08 4.7 1.7 28.5
Aril 10.8 ND ND 3.4 ± 0.2 0.4 0.004 ± 0.0 0.4 (μg/g) 0.1 ± 0.1 0.01 0.1 ± 0.0 0.01 1.2 ± 0.1 0.13 5.4 0.6 ND 1 ND 0.04 0.03 0.4
Stalk 21.7 46.9 ± 1.3 10.2 11.5 ± 0.3 2.5 1.0 ± 0.0 0.2 3.7 ± 0.1 0.8 19.5 ± 0.4 4.2 56.9 ± 1.7 12.3 73.0 15.8 4.0 1 0.09 0.3 1.6 4.9
Leaves 19.5 0.8 ± 0.1 0.2 3.9 ± 0.1 0.7 0.2 ± 0.0 0.04 3.7±.0.3 0.7 5.4 ± 0.2 1.1 2.4 ± 0.2 0.5 16.6 3.2 0.2 1 0.04 0.9 1.4 0.6
Bark 7.5 5.0 ± 0.5 0.4 10.0 ± 0.7 0.8 0.1 ± 0.0 7.5 (μg/g) 2.7 ± 0.6 0.2 15.6 ± 0.6 1.2 209.7 ± 16.9 15.7 242.3 18.2 0.5 1 0.01 0.3 1.5 20.9
Stem 14.8 8.7 ± 0.1 1.3 6.8 ± 0.3 1.0 0..1 ± 0.0 0.02 2.1 ± 0.01 0.3 6.1 ± 0.4 0.9 47.6 ± 5.4 7.0 71.5 10.6 1.2 1 0.01 0.3 0.9 6.9
Aqueous extract
Pericarp 8.6 0.06 ± 0.02 5.2 (μg/g) 3.6 ± 0.1 0.3 0.1 ± 0.0 8.6 (μg/g) 0.4 ± 0.04 0.03 0.1 ± 0.0 8.6 (μg/g) 2.5 ± 0.4 0.2 6.5 0.6 ND 1 0.02 0.1 0.03 0.6
Calyx 18.2 ND ND 2.9 ± 0.1 0.5 ND ND ND ND 0.004 ± 0.0 0.73 (μg/g) ND ND 2.9 0.5 ND 1 ND ND ND ND
Aril 0.8 ND ND 2.9 ± 0.0 0.02 ND ND ND ND 0.01 ± 0.0 0.08 (μg/g) ND ND 2.9 0.002 ND 1 ND ND ND ND
Stalk 13.7 ND ND 2.9 ± 0.1 0.4 ND ND ND ND 0.01 ± 0.0 1.37 (μg/g) ND ND 2.9 0.4 ND 1 ND ND ND ND
Leaves 1.8 ND ND 2.9 ± 0.0 0.05 ND ND 1.4 ± 0.0 0.03 0.04 ± 0.0 0.72 (μg/g) ND ND 4.3 0.08 ND 1 ND 0.4 0.02 ND
Bark 3.8 ND ND 5.3 ± 0.2 0.2 ND ND 0.01 ± 0.0 0.38 (μg/g) 0.2 ± 0.0 7.6 (μg/g) 1.7 ± 0.1 0.06 7.3 0.3 ND 1 ND ND 0.04 0.3
Stem 1.9 ND ND 3.2 ± 0.1 0.1 ND ND 0.03 ± 0.0 0.57 (μg/g) 0.2 ± 0.1 3.8 (μg/g) 0.9 ± 0.1 0.02 4.8 0.009 ND 1 ND 0.01 0.05 0.3

ND: Not determined because the level was below quantification limit. Numbers label: (1) mangostanol; (2) 3-isomangostin; (3) garcinone C; (4) γ-mangostin; (5) 8-deoxygartanin; (6) α-mangostin.

a‘Extract’ means the content of the compounds in the extract, e.g., 8.6 mg of mangostanol is present in each g of methanol extract of pericarp.

b'RW’ means the content of the compounds in the dry powdered raw material, e.g., 3.1 mg of mangostanol is present in each g of dry powdered pericarp raw material.

cThe relative distribution indicates the ratio of the compounds relative to 3-isomangostin. The idea of relative distribution is to indicate the magnitude of the ratio between two compounds, e.g., in methanol extract of pericarp, there is 38.6 times more α-mangostin, 5.4 times more γ-mangostin and 1.1 times more 8-deoxygartanin than 3-isomangostin.

The relative distribution of the xanthones in the methanol extracts showed that α-mangostin was abundant in the pericarp (403.9 mg/g extract), calyx (221.0 mg/g extract), bark (209.7 mg/g extract) and stalk (56.9 mg/g extract). On the other hand, 8-deoxygartanin was abundant in the stalk (19.5 mg/g extract) and leaves (5.4 mg/g extract), whereas, 3-isomangostin was abundant in the aril (3.4 mg/g extract). The distribution of garcinone C was relatively smaller compared with other xanthones. On the contrary, the relative distribution of the xanthones in aqueous extract showed that 3-isomangostin was abundant among the xanthones in all parts of the plant.

Cholinesterase inhibitory activities of the extracts

Cholinesterase inhibitor has been widely accepted as one of the effective strategies for symptomatic treatment of AD20,21. As the disease progress, the activities of AChE declines in certain brain regions to 10–15% of normal activities, whereas BChE activities rise to partially compensate for the loss in AChE activities. Current available drugs for the treatment of AD predominantly are AChE inhibitors. Some investigations showed that BChE might possess as an interesting target for the treatment of AD22.

In this study, the cholinesterase inhibitory activities of the G. mangostana extracts were evaluated. The cholinesterase inhibitory activities of the methanol extracts of different parts of the plant are compared with the aqueous extracts and summarised in Table 3. The methanol and aqueous extracts were initially screened for their cholinesterase inhibitory activities at 100 µg/mL. Extracts that had more than 50% inhibition at 100 µg/mL were further evaluated for their IC50. The IC50 values were in the range of 0.37–72.22 μg/mL for both AChE and BChE. The methanol extracts of the pericarp and calyx showed the most potent inhibitory activities against AChE and BChE enzymes, with IC50 values of 0.90 μg/mL and 0.37 μg/mL, respectively. The methanol extract of calyx was a BChE selective inhibitor with a selectivity index of 26 while the methanol extracts of pericarp and bark are AChE selective inhibitor with a selectivity index of more than 2.

Table 3.

Cholinesterase inhibitory activities of the methanol and aqueous extracts of different parts of Garcinia mangostana.

Sample % of inhibition at 100 µg/mL
IC50 (µg/mL)
Selectivity
AChE BCHE AChE BChE AChE BChE
Methanol extract            
Pericarp 82.19 ± 2.89 74.63 ± 1.03 0.90 ± 0.10 1.94 ± 0.14 2.15 0.46
Calyx 92.92 ± 3.86 94.10 ± 4.12 9.71 ± 1.20 0.37 ± 0.04 0.04 26.24
Aril 22.00 ± 0.48 5.26 ± 0.37 ND ND ND ND
Stalk 65.54 ± 3.51 80.11 ± 0.74 22.81 ± 0.72 20.84 ± 0.02 0.91 1.09
Leaves 32.76 ± 2.09 76.46 ± 1.67 ND 25.83 ± 0.77 ND ND
Bark 83.90 ± 1.35 76.46 ± 0.18 7.88 ± 0.82 19.89 ± 2.68 2.52 0.39
Stem 94.0 3 ± 1.75 89.95 ± 0.78 22.64 ± 0.77 1.82 ± 0.16 0.08 12.44
Aqueous extract            
Pericarp 55.37 ± 1.53 82.59 ± 0.09 52.74 ± 8.98 11.14 ± 0.61 0.21 4.73
Calyx 17.90 ± 3.13 NI ND ND ND ND
Aril NI NI ND ND ND ND
Stalk 59.20 ± 3.60 2.36 ± 0.37 72.22 ± 2.58 ND ND ND
Leaves 15.70 ± 0.93 65.19 ± 0.56 ND 38.81 ± 1.84 ND ND
Bark NI 15.09 ± 8.56 ND ND ND ND
Stem 11.60 ± 1.16 11.23 ± 0.93 ND ND ND ND
Galantamine     0.27 ± 0.07 5.55 ± 0.24 20.55 0.04

Each value represents mean ± SD of triplicates. NI: No inhibition at 100 µg/mL. ND: Not determined.

Selectivity against AChE: IC50BChE/IC50AChE.

Selectivity against BChE: IC50AChE/IC50BChE.

In contrast to the methanol extract, the aqueous extract displayed moderate to poor inhibitory activities against both AChE and BChE. Aqueous extracts of the pericarp and stalk showed moderate inhibitory potency towards AChE, while aqueous extracts of the pericarp and leaves extract demonstrated moderate inhibitory activities against BChE. Our results show that the preicarp extracts from two different extraction solvents exhibit inhibitory activities against both AChE and BChE. In line with the vast differences in cholinesterase inhibitory activities between the extracts from two extraction solvent systems, further analyses were carried out to determine the relationship between xanthone content with the cholinesterase inhibitory activities.

Correlation between xanthone content and cholinesterase inhibitory activities

In the present study, we sought to delineate xanthone content in the different parts of G. mangostana with their cholinesterase activities. Pearson’s correlation analysis revealed that the total xanthone content was significantly correlated with IC50 for AChE (R = −0.780, p < 0.01) and BChE (R = −0.585, p = 0.003). Specifically, a stronger correlation was detected between xanthone content and IC50 of AChE than IC50 of BChE (Figure 3).

Figure 3.

Figure 3.

Scatter plot of IC50 of AChE and BChE versus total xanthone content.

A total of six xanthones, namely α-mangostin, γ-mangostin, 3-isomangostin, 8-deoxygartanin, garcinone C and mangostanol, were detected in the aqueous and/or methanol extracts. Based on the NMDS ordination (Figure 4(A)), the composition of these metabolites in the methanol extracts showed greater variation than the aqueous extract. Three main clusters consisted of (1) pericarp, (2) bark and calyx (3) others were apparent when the samples were labelled based on plant parts (Figure 4(B)). Among the metabolites, α-mangostin and γ-mangostin showed the strongest contribution to the separation along the horizontal axis. Indeed, the bubble plot superimposed on the NMDS showed highest level of α-mangostin and γ-mangostin in pericarp, while the lowest level of both in others (Figure 4(C)). Despite the fact that garcinone C was the most potent AChE inhibitor among the xanthones as reported in our previous study14, the present findings suggest that α-mangostin and γ-mangostin are the key metabolites contributing to the cholinesterase inhibition. For the cholinesterase inhibition, only the methanol extracts of different parts of G. mangostana showed appreciable activities. Based on the activities, the different parts of the plant can be clustered into three groups based on their IC50 values (refer to the box plot in Figure 5). Further statistical analysis revealed a significant difference for the IC50 of AChE between all three clusters (“Pericarp”, “Bark + Calyx”, and “Others”), suggesting that the AChE inhibitory activities of the pericarp is significantly superior to any other parts of the plant. Conversely, that is not the case for BChE inhibition as can be seen by the overlapping between the three clusters. Significant difference in IC50 for BChE was only achieved between “Pericarp” and “Others”.

Figure 4.

Figure 4.

Nonmetric Multidimensional Scaling Ordination of the xanthones. The loading of the variables was projected on the ordination plot. The sample was labelled based on (A) solvent, (B) plant parts. (C) Bubble plot based on the concentration of α-mangostin and γ-mangostin superimposed on the NMDS.

Figure 5.

Figure 5.

Box plot for comparison of IC50 between “Pericarp”, “Bark + Calyx” and “Others”. (A) AChE, (B) BChE.

Our previous paper describes on bioactivity-guided isolation of potential cholinesterase inhibitors from G. mangostana pericarp. We identified six bioactive xanthones, namely α-mangostin, γ-mangostin, mangostanol, 3-isomangostin, garcinone C and 8-deoxygartanin, of which the most potent inhibitor of AChE was garcinone C while γ-mangostin was the most potent inhibitor of BChE14. In the present study, we determined the content of the bioactive xanthones in different parts of the plant to identify the potential source of the bioactive xanthones. In addition, we tested their cholinesterase inhibition to validate our hypothesis that xanthones are the chemical constituents responsible for the cholinesterase inhibitory activities of G. mangostana. The findings clearly support our hypothesis, and this is the first study to show that pericarp has the highest content of xanthones among all the other parts of G. mangostana.

The G. mangostanaextracts showed comparable inhibitory activities to the well known AChE inhibitory plants such as Huperzia23 (the plant is widely used in traditional Chinese medicine to enhance memory from which huperzine A, a commercially available food supplement for the improvement of memory is obtained) and Gingko biloba24 (commonly used to improve memory). It is worth to mention that the methanol extract of G. mangostana pericarp showed more potent AChE inhibition (IC50 of 0.90 µg/mL) compared to Huperzia serrata23 (IC50 of 12.23 µg/mL) and G. biloba24 (IC50 of 252.1 µg/mL). In addition, G. mangostana showed better AChE inhibition than the Ayurvedic medicinal plants used for cognitive disorders25, such as Bacopa monniera (IC50 of 523 µg/mL), Centella asiatica (IC50 of 890 µg/mL), Emblica officinalis (IC50 of 53.5 µg/mL), Glycyrrhiza glabra (IC50 of 418 µg/mL), Tinospora cordifolia (IC50 of 230 µg/mL) and Withania somnifera (IC50 of 124 µg/mL).

Conclusion

In conclusion, methanol extract of the pericarp contained the highest total xanthones among the organic and aqueous extracts of different parts of G. mangostana. α-Mangostin was the major xanthone in the methanol extracts of pericarp, calyx and bark and stem, while 3-isomangostin was the major xanthone in the aqueous extracts of all parts of the plant. On cholinesterase inhibitory potential, the methanol extracts of pericarp and calyx had the most potent inhibitory activities against AChE and BChE with IC50 values of 0.90 and 0.37 µg/mL, respectively. The total xanthone content was found to be well correlated with their cholinesterase inhibitory activities. Since there is an increasing demand for mangosteen products, repurposing of fruit waste (pericarp) enriched with bioactive xanthones has great potential for enhancement of the cognitive health of human beings. The series of prenylated xanthones found in G. mangostana are attractive lead molecules in the field of medicinal chemistry for further structural modification and optimisation in the search of potent cholinesterase inhibitor with favourable pharmacokinetics and safety profiles.

Funding Statement

The authors would like to express their gratitude to Universiti Sains Malaysia and the Ministry of Higher Education Malaysia for providing the research facilities and grant. The project was funded by the Fundamental Research Grant Scheme (FRGS) (203/PFARMASI/6711539) from the Ministry of Higher Education Malaysia.

Author contributions

K.Y.K and V.M. designed the experiment. K.Y.K, V.M. and C.W.C performed the research and analysed data. K.Y.K, C.W.C and V.M. wrote the paper. All authors read and approved the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

References

  • 1.NBJ’s Supplement Business Report . 2015. Available from: https://www.newhope.com/nbj [last accessed 8 Aug 2019].
  • 2.Walker EB. HPLC analysis of selected xanthones in mangosteen fruit. J Sep Sci 2007;30:1229–34. [DOI] [PubMed] [Google Scholar]
  • 3.Pothitirat W, Gritsanapan W.. Thin-layer chromatography-densitometric analysis of alpha-mangostin content in Garcinia mangostana fruit rind extracts. J AOAC Int 2008;91:1145–8. [PubMed] [Google Scholar]
  • 4.Wittenauer J, Falk S, Schweiggert-Weisz U, Carle R.. Characterisation and quantification of xanthones from the aril and pericarp of mangosteens (Garcinia mangostana L.) and a mangosteen containing functional beverage by HPLC–DAD–MSn. Food Chem 2012;134:445–52. [Google Scholar]
  • 5.Ji X, Avula B, Khan IA.. Quantitative and qualitative determination of six xanthones in Garcinia mangostana L. by LC-PDA and LC-ESI-MS. J Pharm Biomed Anal 2007;43:1270–6. [DOI] [PubMed] [Google Scholar]
  • 6.Lahiri DK, Farlow MR, Greig NH, Sambamurti K.. Current drug targets for Alzheimer’s disease treatment. Drug Dev Res 2002;56:267–81. [Google Scholar]
  • 7.Sramek JJ, Zarotsky V, Cutler NR.. Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer’s disease. Drug Dev Res 2002;56:347–53. [Google Scholar]
  • 8.Tougu V. Acetylcholinesterase: Mechanism of catalysis and inhibition. Cent Nerv Syst Agents Med Chem 2001;1:155–70. [Google Scholar]
  • 9.Ballard CG, O'Brien JT, Reichelt K, Perry EK.. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 2002;63:553–8. [DOI] [PubMed] [Google Scholar]
  • 10.Howes MJ, Perry NS, Houghton PJ.. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res 2003;17:1–18. [DOI] [PubMed] [Google Scholar]
  • 11.Sonsalla PK, Wong LY, Harris SL, et al. . Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson’s disease. Exp Neurol 2012;234:482–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, et al. . Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiol Aging 2014;35:2079–90. [DOI] [PubMed] [Google Scholar]
  • 13.Murray AP, Faraoni MB, Castro MJ, et al. . Natural AChE inhibitors from plants and their contribution to Alzheimer’s disease therapy. Curr Neuropharmacol 2013;11:388–413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Khaw KY, Choi SB, Tan SC, et al. . Prenylated xanthones from mangosteen as promising cholinesterase inhibitors and their molecular docking studies. Phytomedicine 2014;21:1303–9. [DOI] [PubMed] [Google Scholar]
  • 15.Khaw KY, Murugaiyah V, Khairuddean M, Tan WN.. Garcinexanthone G, a selective butyrylcholinesterase inhibitor from the stem bark of Garcinia atroviridis. Nat Prod Sci 2018;24:88–92. [Google Scholar]
  • 16.Li P, Yang Z, Tang B, et al. . Identification of xanthones from the mangosteen pericarp that inhibit the growth of Ralstonia solanacearum. ACS Omega 2020; 2020/01/145:334–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kumar V, Chandra S.. LC-ESI/MS determination of xanthone and secoiridoid glycosides from in vitro regenerated and in vivo Swertia chirayita. Physiol Mol Biol Plants 2015;21:51–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mamat SF, Azizan KA, Baharum SN, et al. . GC-MS and LC-MS analyses reveal the distribution of primary and secondary metabolites in mangosteen (Garcinia mangostana Linn.) fruit during ripening. Scientia Horticulturae 2020;262:109004. [Google Scholar]
  • 19.Gondokesumo ME, Pardjianto B, Sumitro SB, et al. . Xanthones analysis and antioxidant activities analysis (applying ESR) of six different maturity levels of mangosteen rind extract (Garcinia mangostana Linn.). Pharmacogn J 2019;11:369–73. [Google Scholar]
  • 20.Fan LY, Chiu MJ.. Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer’s disease. Neuropsychiatr Dis Treat 2014;10:439–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Arnold SE, Kumar A.. Reversible dementias. Med Clin North Am 1993;77:215–30. [DOI] [PubMed] [Google Scholar]
  • 22.Greig NH, Utsuki T, Ingram DK, et al. . Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent . Proc Natl Acad Sci USA 2005;102:17213–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wang Z, Ma Z, Wang L, et al. . Active anti-acetylcholinesterase component of secondary metabolites produced by the endophytic fungi of Huperzia serrata. Electr J Biotechnol 2015;18:399–405. [Google Scholar]
  • 24.Ding X, Ouyang MA, Liu X, Wang RZ.. Acetylcholinesterase inhibitory activities of flavonoids from the leaves of Ginkgo biloba against brown planthopper. J Chem 2013; 2013:1–4. [Google Scholar]
  • 25.Mathew M, Subramanian S.. In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of Ayurvedic medicinal plants used for cognitive disorders. PLOS One 2014;9:e86804. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Enzyme Inhibition and Medicinal Chemistry are provided here courtesy of Taylor & Francis

RESOURCES